This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Learn what can go wrong with a bond ladder and how to prevent issues. Identify warning signs and practical fixes to stay on course.
27,765 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
With $5,000, you can build a solid starter portfolio that balances growth and risk. This guide shows a simple, repeat...
Oil prices rebounded today, lifting energy stocks. ExxonMobil led gains as the market priced in stronger cash flow, s...
A fresh, investor-ready look at StoneX's Q2 2026 results. This article breaks down the key numbers, what they mean fo...
An 8% year rise in a regulated water utility stock and a major investor trimming a $28 million stake highlight how to...
Berkshire Hathaway is sitting on an enormous cash reserve. Far from a weakness, that cash pile gives the company dry ...
A dramatic legal verdict against a tech titan could reshape how investors view AI, crypto, and venture risk. This art...
Walmart recently released its latest quarterly results, but the stock moved on macro concerns as much as fundamentals...
The billionaire bill gates' foundation recently remade its public equity lineup, selling its Microsoft stake and conc...
When great news KLAC stock hits the headlines, investors want a clear game plan. This guide breaks down the potential...
Li Auto's 2026 earnings outlook hinges on shipments, margins, and smart capital allocation. This deep dive breaks dow...
A single conference-call moment changed the mood around Eli Lilly. By unpacking eight key themes from the CEO, invest...